Premium
Treatment with anti‐Sclerostin antibody to stimulate mandibular bone formation
Author(s) -
Tamplen Matthew,
Fowler Tristan,
Markey Jeffery,
Knott P. Daniel,
Suva Larry J.,
Alliston Tamara
Publication year - 2018
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.25128
Subject(s) - sclerostin , bone formation , medicine , antibody , endocrinology , chemistry , wnt signaling pathway , signal transduction , immunology , biochemistry
Background Anti‐Sclerostin antibody (Scl‐Ab) is a promising new bone anabolic therapy. Although anti‐Scl‐Ab stimulates bone formation and repair in the appendicular and axial skeleton, its efficacy in the craniofacial skeleton is still poorly understood. Methods Using an established model of Down syndrome‐dependent bone deficiency, 10 Ts65Dn mice and 10 wild‐type mice were treated weekly via i.v. tail vein injection with vehicle or anti‐Sclerostin for 3 weeks and euthanized 1 week after. Results Wild‐type mice treated with the anti‐Scl‐Ab had increased mandibular bone, trabecular thickness, and alveolar height compared with controls. Anti‐Scl‐Ab increased Ts65Dn mandibular bone parameters such that they were statistically indistinguishable from those in vehicle‐treated wild‐type mandibles. Conclusion Treatment with anti‐Scl‐Ab significantly increased mandibular bone mass and alveolar height in wild type mice and normalized mandibular bone mass and alveolar height in Ts65Dn mice. The anti‐Scl‐Ab therapy represents a novel method for increasing mandibular bone formation.